AAAAAA

   
Results: 1-15 |
Results: 15
FOR WHICH PATIENTS WITH AGGRESSIVE NON-HODGKINS-LYMPHOMA IS PROPHYLAXIS FOR CENTRAL-NERVOUS-SYSTEM DISEASE MANDATORY
Authors: BOS GMJ VANPUTTEN WLJ VANDERHOLT B VANDENBENT M VERDONCK LF HAGENBEEK A
Citation: Gmj. Bos et al., FOR WHICH PATIENTS WITH AGGRESSIVE NON-HODGKINS-LYMPHOMA IS PROPHYLAXIS FOR CENTRAL-NERVOUS-SYSTEM DISEASE MANDATORY, Annals of oncology, 9(2), 1998, pp. 191-194
VAD AND INTERMEDIATE-DOSE MELPHALAN (IDM) INDUCTION THERAPY FOLLOWED BY STEM-CELL TRANSPLANTATION IN MULTIPLE-MYELOMA - RESULTS OF A PHASE-II AND PRELIMINARY-RESULTS OF A RANDOMIZED PHASE-III STUDY
Authors: LOKHORST HM SONNEVELD P CORNELISSEN JJ CROOCKEWIT S VANDERHOLT B KOOY MV VANOERS RHJ RICHEL D SEGEREN C VELLENGA E VERDONCK LF VERHOEF G WIJERMANS PW
Citation: Hm. Lokhorst et al., VAD AND INTERMEDIATE-DOSE MELPHALAN (IDM) INDUCTION THERAPY FOLLOWED BY STEM-CELL TRANSPLANTATION IN MULTIPLE-MYELOMA - RESULTS OF A PHASE-II AND PRELIMINARY-RESULTS OF A RANDOMIZED PHASE-III STUDY, Bone marrow transplantation, 21, 1998, pp. 709-709
VAD AND INTERMEDIATE-DOSE MELPHALAN (IDM) FOLLOWED BY STEM-CELL TRANSPLANTATION IN MULTIPLE-MYELOMA - RESULTS OF A PHASE-II AND PRELIMINARY-RESULTS OF A RANDOMIZED PHASE-III STUDY
Authors: LOKHORST HM SONNEVELD P CORNELISSEN JJ CROOCKEWIT S VANDERHOLT B KOOY MV VANOERS RHJ RICHEL D SEGEREN C VELLENGA E VERDONCK LF VERHOEF G WIJERMANS PW
Citation: Hm. Lokhorst et al., VAD AND INTERMEDIATE-DOSE MELPHALAN (IDM) FOLLOWED BY STEM-CELL TRANSPLANTATION IN MULTIPLE-MYELOMA - RESULTS OF A PHASE-II AND PRELIMINARY-RESULTS OF A RANDOMIZED PHASE-III STUDY, British Journal of Haematology, 102(1), 1998, pp. 6-7
TRANSPLANT-RELATED MORTALITY FOLLOWING ALLOGENEIC BMT IN CMV SEROPOSITIVE DONOR RECIPIENT PAIRS IS INCREASED DESPITE EFFICACIOUS PREVENTIONOF CMV DISEASE BY PREEMPTIVE THERAPY WITH GANCICLOVIR/
Authors: BROERS A HENZENLOGMANS S KUENENBOUMEESTER V DELARIVIERE GB VANDERHOLT B LOWENBERG B CORNELISSEN JJ
Citation: A. Broers et al., TRANSPLANT-RELATED MORTALITY FOLLOWING ALLOGENEIC BMT IN CMV SEROPOSITIVE DONOR RECIPIENT PAIRS IS INCREASED DESPITE EFFICACIOUS PREVENTIONOF CMV DISEASE BY PREEMPTIVE THERAPY WITH GANCICLOVIR/, British Journal of Haematology, 102(1), 1998, pp. 13-13
EFFICACY OF STANDARD CHOP CHEMOTHERAPY IN ELDERLY PATIENTS WITH POOR-RISK NON-HODGKINS-LYMPHOMA (NHL)
Authors: DOORDUIJN JK VANDERHOLT B BREED WPM VANDERHEM KG VANIMHOFF GW KRAMER MHH KOOY MV VANOERS MHJ OSSENKOPPELE GJ RICHEL DJ ROOZENDAAL KJ VANTVEER MB VERDONCK LF VERHOEF G WIJERMANS PW SONNEVELD P
Citation: Jk. Doorduijn et al., EFFICACY OF STANDARD CHOP CHEMOTHERAPY IN ELDERLY PATIENTS WITH POOR-RISK NON-HODGKINS-LYMPHOMA (NHL), British Journal of Haematology, 102(1), 1998, pp. 149-149
REDUCTION OF INTERLABORATORY VARIABILITY IN FLOW CYTOMETRIC IMMUNOPHENOTYPING BY STANDARDIZATION OF INSTRUMENT SET-UP AND CALIBRATION, AND STANDARD LIST MODE DATA-ANALYSIS
Authors: GRATAMA JW KRAAN J ADRIAANSEN H HOOIBRINK B LEVERING W REINDERS P VANDENBEEMD MWM VANDERHOLT B BOLHUIS RLH
Citation: Jw. Gratama et al., REDUCTION OF INTERLABORATORY VARIABILITY IN FLOW CYTOMETRIC IMMUNOPHENOTYPING BY STANDARDIZATION OF INSTRUMENT SET-UP AND CALIBRATION, AND STANDARD LIST MODE DATA-ANALYSIS, Cytometry, 30(1), 1997, pp. 10-22
ANALYSIS OF FACTORS CONTRIBUTING TO THE FORMATION OF MONONUCLEAR CELLAGGREGATES (ESCAPEES) IN FLOW CYTOMETRIC IMMUNOPHENOTYPING
Authors: GRATAMA JW VANDERLINDEN R VANDERHOLT B BOLHUIS RLH VANDEWINKEL JGJ
Citation: Jw. Gratama et al., ANALYSIS OF FACTORS CONTRIBUTING TO THE FORMATION OF MONONUCLEAR CELLAGGREGATES (ESCAPEES) IN FLOW CYTOMETRIC IMMUNOPHENOTYPING, Cytometry, 29(3), 1997, pp. 250-260
EPIDURAL ABSCESS COMPLICATING EPIDURAL ANALGESIA IN CHRONIC MALIGNANTPAIN
Authors: SMITT PAES TSAFKA A TENGVANDEZANDE F VECHT CJ VANDERHOLT B VANDENBENT MJ
Citation: Paes. Smitt et al., EPIDURAL ABSCESS COMPLICATING EPIDURAL ANALGESIA IN CHRONIC MALIGNANTPAIN, Neurology, 48(3), 1997, pp. 1014-1014
MDR-1 EXPRESSION IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RESPONSE ANDSURVIVAL IN DE-NOVO ACUTE MYELOID-LEUKEMIA
Authors: VANDENHEUVELEIBRINK MM VANDERHOLT B TEBOEKHORST PAW PIETERS R SCHOESTER M LOWENBERG B SONNEVELD P
Citation: Mm. Vandenheuveleibrink et al., MDR-1 EXPRESSION IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RESPONSE ANDSURVIVAL IN DE-NOVO ACUTE MYELOID-LEUKEMIA, British Journal of Haematology, 99(1), 1997, pp. 76-83
VAD ADMINISTERED AS INTRAVENOUS PUSH INJECTION AS FIRST-LINE TREATMENT IN STAGE II III MULTIPLE-MYELOMA/
Authors: SEGEREN CM VANDERHOLT B SONNEVELD P CROOCKEWIT S VELLENGA E VANOERS MHJ RICHEL D VERHOEF G CORNELISSEN JJ LOKHORST HM
Citation: Cm. Segeren et al., VAD ADMINISTERED AS INTRAVENOUS PUSH INJECTION AS FIRST-LINE TREATMENT IN STAGE II III MULTIPLE-MYELOMA/, Blood, 90(10), 1997, pp. 1591-1591
THE PEDICLED OMENTOPLASTY AND SPLIT SKIN-GRAFT (POSSG) FOR RECONSTRUCTION OF LARGE CHEST-WALL DEFECTS - A VALIDITY STUDY OF 34 PATIENTS
Authors: CONTANT CME VANGEEL AN VANDERHOLT B WIGGERS T
Citation: Cme. Contant et al., THE PEDICLED OMENTOPLASTY AND SPLIT SKIN-GRAFT (POSSG) FOR RECONSTRUCTION OF LARGE CHEST-WALL DEFECTS - A VALIDITY STUDY OF 34 PATIENTS, European journal of surgical oncology, 22(5), 1996, pp. 532-537
IN-VIVO FLUORESCENCE KINETICS AND LOCALIZATION OF ALUMINUM PHTHALOCYANINE DISULFONATE IN AN AUTOLOGOUS TUMOR-MODEL
Authors: WITJES MJH SPEELMAN OC NIKKELS PGJ NOOREN CAAM NAUTA JM VANDERHOLT B VANLEENGOED HLLM STAR WM ROODENBURG JLN
Citation: Mjh. Witjes et al., IN-VIVO FLUORESCENCE KINETICS AND LOCALIZATION OF ALUMINUM PHTHALOCYANINE DISULFONATE IN AN AUTOLOGOUS TUMOR-MODEL, British Journal of Cancer, 73(5), 1996, pp. 573-580
MDR-1 EXPRESSION IS A SIGNIFICANT ADVERSE PROGNOSTIC FACTOR IN DE-NOVO AML FOR CR AND SURVIVAL AND IS INDEPENDENT FROM AGE, KARYOTYPE AND PHENOTYPE
Authors: VANDENHEUVELEIBRINK MM VANDERHOLT B TEBOEKHORST PAW PIETERS R LOWENBERG B SCHOESTER M SONNEVELD P
Citation: Mm. Vandenheuveleibrink et al., MDR-1 EXPRESSION IS A SIGNIFICANT ADVERSE PROGNOSTIC FACTOR IN DE-NOVO AML FOR CR AND SURVIVAL AND IS INDEPENDENT FROM AGE, KARYOTYPE AND PHENOTYPE, Blood, 88(10), 1996, pp. 1428-1428
HETEROGENEITY IN THE IN-VITRO SURVIVAL AND PROLIFERATION OF HUMAN SEMINOMA CELLS
Authors: OLIE RA LOOIJENGA LHJ DEKKER MC DEJONG FH VANDISSELEMILIANI F DEROOIJ DG VANDERHOLT B OOSTERHUIS JW
Citation: Ra. Olie et al., HETEROGENEITY IN THE IN-VITRO SURVIVAL AND PROLIFERATION OF HUMAN SEMINOMA CELLS, British Journal of Cancer, 71(1), 1995, pp. 13-17
RANDOMIZED PHASE-II STUDY ON THE VALUE OF G-CSF (FILGRASTIM) IN COMBINATION WITH STANDARD INDUCTION CHEMOTHERAPY IN MYELODYSPLASTIC SYNDROMES (MDS)
Authors: OSSENKOPPELE GJ VERHOEF GEG VANDERHOLT B VERDONCK LF VELLENGA E SONNEVELD P VANDERLELIE J WIJERMANS PW LOWENBERG B
Citation: Gj. Ossenkoppele et al., RANDOMIZED PHASE-II STUDY ON THE VALUE OF G-CSF (FILGRASTIM) IN COMBINATION WITH STANDARD INDUCTION CHEMOTHERAPY IN MYELODYSPLASTIC SYNDROMES (MDS), Blood, 86(10), 1995, pp. 1338-1338
Risultati: 1-15 |